| name | endo-avoid-random-gh-diagnosis |
| description | Recommends against using random GH levels to diagnose acromegaly because of pulsatile secretion. Use when a clinician considers ordering a random GH test to evaluate for acromegaly in a patient with suggestive features. |
Avoid random GH measurement for acromegaly diagnosis
STEP 1 — Gather Information
Collect clinical features suggestive of acromegaly (e.g., acral enlargement, facial changes, comorbidities such as diabetes, hypertension, sleep apnea, carpal tunnel syndrome) and determine if a random GH test is being considered for diagnosis.
STEP 2 — Rule In / Rule Out
If a random GH test is being considered to evaluate for acromegaly, proceed to step 3; otherwise, do not order random GH and end evaluation.
STEP 3 — Classify or Stratify
Classify the scenario as “random GH not recommended for diagnosis” per guideline recommendation against reliance on random GH levels.
STEP 4 — Decide
Do not order random GH; instead, order serum IGF-1 as the initial screening test for acromegaly.
Clinical Guardrails / Mimics / Pitfalls
Do not interpret random GH levels as diagnostic or use them to rule in/out acromegaly; avoid relying on single random GH due to pulsatile secretion; use IGF-1 and OGTT with glucose suppression for confirmation.
Concrete Clinical Example
A 48‑year‑old presents with shoe size increase, jaw protrusion, and fatigue; the clinician considers ordering a random GH test. Following the skill, they order IGF‑1 instead; an elevated IGF‑1 prompts an OGTT to assess GH suppression.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
